Indonesia's Ministry of Health and Philips to deliver nationwide coverage of advanced image-guided therapy systems in Indonesia, expanding access to cardiac, stroke and cancer care in all 38 provinces
Amsterdam, the Netherlands and Jakarta, Indonesia – In a major step toward transforming healthcare delivery,
Royal Philips
(NYSE: PHG, AEX: PHIA), a global leader in health technology and the Indonesia's Ministry of Health today announced plans to deploy state-of-the-art image-guided therapy systems nationwide, as part of their signed agreements, under the Strengthening Indonesia's Healthcare Referral Network (SIHREN) project.
The landmark agreements, recently awarded to Philips after an international, competitive bidding process, combine cutting-edge treatment technology, services and training to strengthen Indonesia's health infrastructure. The initiative aims to transform the country's treatment for heart disease, stroke and cancer – Indonesia's leading causes of death – by expanding access to cutting-edge technologies and care in all 38 provinces, from Aceh to Papua. This initiative is set to benefit millions of patients across Indonesia.
The SIHREN project is an ambitious effort jointly funded by the World Bank and other multilateral development banks to support Indonesia's health transformation agenda by significantly improving referral healthcare.
Challenges in ensuring equitable access to healthcare
With a population exceeding 280 million, Indonesia is the world's fourth most populous nation. As a vast archipelago of over 17,000 islands, it faces significant challenges in ensuring equitable access to healthcare. The country is also grappling with a surge in non-communicable diseases (NCDs) such as heart disease, stroke and cancer – conditions projected to impose a staggering economic burden of USD 4.47 trillion [1]. And yet, advanced care for these illnesses remains largely centralized on the densely populated island of Java, leaving much of the country underserved.
The initiative will establish a nationwide network of advanced image-guided therapy rooms, dramatically expanding access to minimally invasive treatments across hundreds of hospitals in all 38 provinces. The Ministry of Health has made a long-term commitment to delivering nationwide coverage of the Azurion platform, aligned to local hospital infrastructure and patient population needs.
A study published in the Journal of Minimally Invasive Surgery [2] found that minimally invasive techniques significantly reduce postoperative pain, recovery time, and hospital stays compared to traditional open surgeries.
'Delivering better care for more people requires strong partnerships and the best innovations,' said Roy Jakobs, CEO of Royal Philips. 'We're honored to be Indonesia's partner of choice to deliver our innovation directly where it's needed most. More patients in Indonesia will now have access to better care.'
'Minimally invasive care is life-changing for patients, unlocking treatment options that were once unimaginable. With small incisions, such targeted treatments can mean shorter hospital stays, fewer complications and quicker recoveries for patients,' said Carla Goulart Peron, Chief Medical Officer at Philips. 'From opening heart-attack-causing blockages, to treating strokes and targeting cancer tumors, image-guided, minimally invasive therapy will be a game-changer for NCD care in Indonesia.'
Philips maintains a strong footprint in Indonesia, employing over 3,900 people across 12 cities and operating a manufacturing facility in Batam for its Personal Health businesses. The Philips Foundation recently launched
a major partnership with World Child Cancer to advance early detection of childhood cancers
across the country.
'We remain committed to supporting healthcare transformation by delivering innovations that provide better outcome for patient and improve experience for healthcare workers,' said Astri R. Dharmawan, President Director of Philips Indonesia. 'Our combined efforts with the Indonesian government will help close healthcare gaps and bring us closer to a Healthy Indonesia.'
[1]
https://www3.weforum.org/docs/WEF_The_Economics_of_non_Disease_Indonesia_2015.pdf
[2]
https://pubmed.ncbi.nlm.nih.gov/14746519/
For further information, please contact:
Michael Fuchs
Global External Relations Director, Philips
Tel.: +31 614 869 261
E-mail:
michael.fuchs@philips.com
Jane Yeo
Head of Brand and Communications APAC, Philips
Tel.: +65 9618 7397
E-mail:
jane.yeo@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips' patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.
Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,300 employees with sales and services in more than 100 countries. News about Philips can be found at
www.philips.com/newscenter
.
Attachments
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
What To Expect From Hims & Hers Health's (HIMS) Q2 Earnings
Telehealth company Hims & Hers Health (NYSE:HIMS) will be reporting results this Monday after market hours. Here's what to expect. Hims & Hers Health beat analysts' revenue expectations by 8.3% last quarter, reporting revenues of $586 million, up 111% year on year. It was a strong quarter for the company, with a solid beat of analysts' EPS estimates and full-year EBITDA guidance beating analysts' expectations. It added 137,000 customers to reach a total of 2.37 million. Is Hims & Hers Health a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Hims & Hers Health's revenue to grow 74.5% year on year to $550.8 million, improving from the 51.8% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.23 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Hims & Hers Health has only missed Wall Street's revenue estimates once over the last two years, exceeding top-line expectations by 3.2% on average. Looking at Hims & Hers Health's peers in the healthcare technology segment, only Omnicell has reported results so far. It beat analysts' revenue estimates by 4.9%, delivering year-on-year sales growth of 5%. The stock price was unchanged following the results. Read our full analysis of Omnicell's earnings results here. Debates around the economy's health and the impact of potential tariffs and corporate tax cuts have caused much uncertainty in 2025. While some of the healthcare technology stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.3% on average over the last month. Hims & Hers Health is up 29% during the same time and is heading into earnings with an average analyst price target of $48.36 (compared to the current share price of $62.48). Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Encompass Health (EHC) Reports Q2: Everything You Need To Know Ahead Of Earnings
Health care services provider Encompass Health (NYSE:EHC) will be announcing earnings results this Monday afternoon. Here's what you need to know. Encompass Health beat analysts' revenue expectations by 1.7% last quarter, reporting revenues of $1.46 billion, up 10.6% year on year. It was a strong quarter for the company, with an impressive beat of analysts' full-year EPS guidance estimates and a solid beat of analysts' EPS estimates. Is Encompass Health a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Encompass Health's revenue to grow 9.6% year on year to $1.43 billion, in line with the 9.6% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.21 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Encompass Health has only missed Wall Street's revenue estimates once over the last two years, exceeding top-line expectations by 1.5% on average. Looking at Encompass Health's peers in the healthcare providers & services segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Select Medical delivered year-on-year revenue growth of 4.5%, meeting analysts' expectations, and CVS Health reported revenues up 8.4%, topping estimates by 5.1%. Select Medical traded down 15.1% following the results while CVS Health's stock price was unchanged. Read our full analysis of Select Medical's results here and CVS Health's results here. Questions about potential tariffs and corporate tax changes have caused much volatility in 2025. While some of the healthcare providers & services stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.3% on average over the last month. Encompass Health is down 9.1% during the same time and is heading into earnings with an average analyst price target of $131.58 (compared to the current share price of $108.53). When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we've found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
Yahoo
an hour ago
- Yahoo
The 3 Things That Matter for Pfizer Now
Key Points Pfizer's oncology pipeline looks promising. The company's newer approvals could make significant progress. And its efforts to reduce expenses should help it navigate tariff-related challenges. 10 stocks we like better than Pfizer › Once a market darling during the early pandemic years, Pfizer (NYSE: PFE) has been on a straight southbound path for several years now. The company's shares are down by 50% since 2022. Some investors might see this as an opportunity to buy the stock on the dip, but that'd only be a good move if there are excellent reasons to think the stock might bounce back. There are several things investors can watch out for to determine this. Let's consider three of the most important. 1. Pfizer's oncology pipeline Any struggling pharmaceutical company will try to turn things around by developing newer medicines. Pfizer is no exception; its pipeline is deep, with over 100 active programs. The drugmaker is particularly focused on making a significant impact in the oncology market, one of the largest segments in the industry. That's why Pfizer spent $43 billion to acquire Seagen, a smaller biotech that specialized in oncology. At the time of the acquisition, Seagen had several approved cancer drugs, but it had an especially impressive pipeline for a company of its size. Pfizer's CEO said: "We are not buying the golden eggs. We are acquiring the goose that is laying the golden eggs." The idea was that Seagen's innovative abilities, coupled with Pfizer's resources and vast experience and reach in the industry, would eventually produce even better outcomes. Pfizer has made other moves to bolster its oncology pipeline since that acquisition. Earlier this year, it signed a licensing agreement with China-based 3SBio for SSGJ-707, an investigational bispecific antibody -- a niche that is increasingly gaining ground in oncology. Pfizer's clinical and regulatory progress in this market will be crucial in the next few years. Investors should closely monitor the company's oncology-related developments. 2. The progress of newer approvals The drugmaker has earned approval for several new medicines in recent years. These include Abrysvo, a vaccine for the respiratory syncytial virus (RSV); cancer medicine Elrexfio; and Litfulo, which treats alopecia areata. Unfortunately, none of these is making significant contributions to Pfizer's top line yet. That said, they haven't been on the market for that long; all were first approved in 2023. There's still time for these newer products to make a more meaningful impact on Pfizer's financial results, especially as they gain new indications. For instance, Abrysvo recently got a label expansion in Europe, allowing it to be prescribed to lower the risk of respiratory tract disease caused by RSV in people aged 18 to 59. Litfulo is undergoing clinical trials targeting Crohn's disease, ulcerative colitis, and vitiligo. Elrexfio is also in several phase 3 studies for additional indications. Investors should check on clinical and regulatory progress for these and other newer drugs in Pfizer's arsenal. 3. Pfizer's cost-cutting efforts Pfizer has been looking to boost its bottom line by reducing expenses. The company set a cost-savings target of $4.5 billion for this year, and during the first quarter, management said it was on track to achieve that. These efforts matter for at least two reasons. First, any company -- especially one whose revenue growth is as inconsistent as Pfizer's has been in recent years -- can benefit from cutting expenses, so long as doing so doesn't hurt other aspects of its business. Second, with President Donald Trump's tariffs threatening to increase manufacturing costs for pharmaceutical companies, Pfizer's efforts could help mitigate the impact of the administration's trade policies. So, that's something else to watch out for. Is Pfizer's stock a buy? Though Pfizer has not performed well recently and will encounter some critical patent cliffs within the next few years (notably, that of its anticoagulant Eliquis), there are good reasons for long-term investors to consider the stock. One is that shares look far too cheap at current levels. The company's forward price-to-earnings ratio was recently 8.3, which is much lower than the healthcare industry's average of 16.5. Another is that the drugmaker's extensive pipeline should enable it to overcome recent challenges to revenue growth in the long run. Finally, Pfizer is also a decent dividend stock. So, despite some challenges, it's still worth serious consideration. Should you invest $1,000 in Pfizer right now? Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* Now, it's worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Pfizer. The Motley Fool has a disclosure policy. The 3 Things That Matter for Pfizer Now was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
